Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Entera Bio Ltd.ENTX · Entity 5464 | Director | January 01, 2026 | January 02, 2026 |
| TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063 | Director | June 05, 2026 | June 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Entera Bio Ltd.
Report date January 01, 2026 · Filed January 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary Shares, par value NIS 0.0000769 per shareSEC Table I · non-derivative | Direct | 338,454 |
Reported balance
After 2026-01-01 transaction · row 1
1 source rowRow 1 · 2026-01-01 · Grant · Acquired 38,294 · Balance 338,454 F1: The Board of Directors ("Board") of Entera Bio Ltd. (the "Company") awarded these shares to the Reporting Persons in lieu of the cash fees the Reported Person was entitled to for services rendered as a director of the Company for the 2025 fiscal year. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.94 · Expires 2036-01-01 | Direct | 33,505 |
Reported balance
After 2026-01-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-01-01 · Grant · Acquired 33,505 · Balance 33,505 F3: These options represent the Board's annual grant of options to directors of the Company. The options vest ratably on a quarterly basis over a one-year period that commenced on January 1, 2026. |
| Ordinary Shares, par value NIS 0.0000769 per shareSEC Table I · non-derivative | IndirectBy Trust | 6,200 |
Reported balance
Holding disclosure · report date 2026-01-01 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 6,200 F2: These shares are owned by a Trust of which the Reporting Person's grandchild is the beneficiary, and the Reporting Person's spouse is the Trustee. The Reporting Person disclaims beneficial ownership of the securities held by this trust, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| Ordinary Shares, par value NIS 0.0000769 per shareSEC Table I · non-derivative | IndirectBy Trust | 6,200 |
Reported balance
Holding disclosure · report date 2026-01-01 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 6,200 F2: These shares are owned by a Trust of which the Reporting Person's grandchild is the beneficiary, and the Reporting Person's spouse is the Trustee. The Reporting Person disclaims beneficial ownership of the securities held by this trust, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| Ordinary Shares, par value NIS 0.0000769 per shareSEC Table I · non-derivative | IndirectBy Trust | 6,200 |
Reported balance
Holding disclosure · report date 2026-01-01 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 6,200 F2: These shares are owned by a Trust of which the Reporting Person's grandchild is the beneficiary, and the Reporting Person's spouse is the Trustee. The Reporting Person disclaims beneficial ownership of the securities held by this trust, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| Ordinary Shares, par value NIS 0.0000769 per shareSEC Table I · non-derivative | IndirectBy Trust | 6,200 |
Reported balance
Holding disclosure · report date 2026-01-01 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 6,200 F2: These shares are owned by a Trust of which the Reporting Person's grandchild is the beneficiary, and the Reporting Person's spouse is the Trustee. The Reporting Person disclaims beneficial ownership of the securities held by this trust, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The Board of Directors ("Board") of Entera Bio Ltd. (the "Company") awarded these shares to the Reporting Persons in lieu of the cash fees the Reported Person was entitled to for services rendered as a director of the Company for the 2025 fiscal year.
F2: These shares are owned by a Trust of which the Reporting Person's grandchild is the beneficiary, and the Reporting Person's spouse is the Trustee. The Reporting Person disclaims beneficial ownership of the securities held by this trust, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
F3: These options represent the Board's annual grant of options to directors of the Company. The options vest ratably on a quarterly basis over a one-year period that commenced on January 1, 2026.
TEVA PHARMACEUTICAL INDUSTRIES LTD
Report date June 05, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 130,149 |
Reported balance
After 2026-06-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-05 · Exercise / conversion · Acquired 14,492 · Balance 130,149 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-05 · Exercise / conversion · Disposed 14,492 · Balance 0 F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3: Restricted share units were granted on June 5, 2025 and vested on June 5, 2026. F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F3: Restricted share units were granted on June 5, 2025 and vested on June 5, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2026 Filed Jun 8, 2026 20:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 14,492 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-261691 · ownership.xml · derivative · entry 2 LIEBERMAN GERALD M · CIK 0001234346 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 14,492 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on June 5, 2025 and vested on June 5, 2026. F3 · derivative.expiration_date: Restricted share units were granted on June 5, 2025 and vested on June 5, 2026. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 05, 2026 Filed Jun 8, 2026 20:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 14,492 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-261691 · ownership.xml · nonDerivative · entry 1 LIEBERMAN GERALD M · CIK 0001234346 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,149 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| May 28, 2026 Filed Jun 1, 2026 20:11 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 7,242 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-251434 · ownership.xml · derivative · entry 1 LIEBERMAN GERALD M · CIK 0001234346 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,242 Underlying: Ordinary Shares · 7,242 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on May 28, 2026 and vest on May 28, 2027. F2 · derivative.expiration_date: Restricted share units were granted on May 28, 2026 and vest on May 28, 2027. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| January 01, 2026 Filed Jan 2, 2026 21:21 UTC | Entera Bio Ltd. ENTX · Entity 5464 | GrantStock Option (right to buy) · Derivative | 33,505 | $0.00 Strike: $1.94 | $0.00 |
DisclosureSEC source: 0001178913-26-000016 · ownership.xml · derivative · entry 6 LIEBERMAN GERALD M · CIK 0001234346 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,505 Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 33,505 shares Expires 2036-01-01 F3 · derivative.exercise_date: These options represent the Board's annual grant of options to directors of the Company. The options vest ratably on a quarterly basis over a one-year period that commenced on January 1, 2026. Read SEC document |
| January 01, 2026 Filed Jan 2, 2026 21:21 UTC | Entera Bio Ltd. ENTX · Entity 5464 | GrantOrdinary Shares, par value NIS 0.0000769 per share | 38,294 | $0.00 | $0.00 |
DisclosureSEC source: 0001178913-26-000016 · ownership.xml · nonDerivative · entry 1 LIEBERMAN GERALD M · CIK 0001234346 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 338,454 F1 · kind: The Board of Directors ("Board") of Entera Bio Ltd. (the "Company") awarded these shares to the Reporting Persons in lieu of the cash fees the Reported Person was entitled to for services rendered as a director of the Company for the 2025 fiscal year. Read SEC document |
| June 06, 2025 Filed Jun 9, 2025 20:13 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 9,632 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-083736 · ownership.xml · derivative · entry 2 LIEBERMAN GERALD M · CIK 0001234346 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 9,632 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on June 6, 2024 and vested on June 6, 2025. F3 · derivative.expiration_date: Restricted share units were granted on June 6, 2024 and vested on June 6, 2025. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 06, 2025 Filed Jun 9, 2025 20:13 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 9,632 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-083736 · ownership.xml · nonDerivative · entry 1 LIEBERMAN GERALD M · CIK 0001234346 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,657 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:13 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 14,492 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-083736 · ownership.xml · derivative · entry 3 LIEBERMAN GERALD M · CIK 0001234346 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,492 Underlying: Ordinary Shares · 14,492 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on June 5, 2025 and vest on June 5, 2026. F4 · derivative.expiration_date: Restricted share units were granted on June 5, 2025 and vest on June 5, 2026. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:06 UTC | Entera Bio Ltd. ENTX · Entity 5464 | Exercise / conversionWarrant (right to buy) · Derivative | 23,952 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001178913-25-001192 · ownership.xml · derivative · entry 6 LIEBERMAN GERALD M · CIK 0001234346 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,509 Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 23,952 shares Expires 2028-12-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:06 UTC | Entera Bio Ltd. ENTX · Entity 5464 | Exercise / conversionOrdinary Shares, par value NIS 0.0000769 per share | 23,952 | $1.00 | $23,952.00 |
DisclosureSEC source: 0001178913-25-001192 · ownership.xml · nonDerivative · entry 1 LIEBERMAN GERALD M · CIK 0001234346 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,160 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 15, 2025 Filed Jan 17, 2025 21:30 UTC | Entera Bio Ltd. ENTX · Entity 5464 | GrantStock Option (right to buy) · Derivative | 28,509 | $0.00 Strike: $2.28 | $0.00 |
DisclosureSEC source: 0001178913-25-000156 · ownership.xml · derivative · entry 6 LIEBERMAN GERALD M · CIK 0001234346 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,509 Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 28,509 shares Expires 2035-01-15 F6 · derivative.exercise_date: These options represent the Board's annual grant of options to directors of the Company. The options vest ratably on a quarterly basis over a one-year period that commenced on January 1, 2025. Read SEC document |
| January 15, 2025 Filed Jan 17, 2025 21:30 UTC | Entera Bio Ltd. ENTX · Entity 5464 | GrantOrdinary Shares, par value NIS 0.0000769 per share | 10,717 | $0.00 | $0.00 |
DisclosureSEC source: 0001178913-25-000156 · ownership.xml · nonDerivative · entry 1 LIEBERMAN GERALD M · CIK 0001234346 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 276,208 F1 · kind: The Board of Directors ("Board") of Entera Bio Ltd. (the "Company") awarded these shares to the Reporting Persons in lieu of the cash fees the Reported Person was entitled to for services rendered as a director of the Company for the fourth quarter of 2024. Read SEC document |
| October 02, 2024 Filed Oct 4, 2024 20:06 UTC | Entera Bio Ltd. ENTX · Entity 5464 | GrantOrdinary Shares, par value NIS 0.0000769 per share | 11,269 | $0.00 | $0.00 |
DisclosureSEC source: 0001178913-24-003216 · ownership.xml · nonDerivative · entry 1 LIEBERMAN GERALD M · CIK 0001234346 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 265,491 Read SEC document |
| August 27, 2024 Filed Aug 29, 2024 20:27 UTC | Entera Bio Ltd. ENTX · Entity 5464 | GrantOrdinary Shares, par value NIS 0.0000769 per share | 27,261 | $0.00 | $0.00 |
DisclosureSEC source: 0001178913-24-002887 · ownership.xml · nonDerivative · entry 1 LIEBERMAN GERALD M · CIK 0001234346 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 254,222 Read SEC document |
| June 15, 2024 Filed Jun 17, 2024 11:20 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 21,108 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-074009 · ownership.xml · derivative · entry 2 LIEBERMAN GERALD M · CIK 0001234346 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 21,108 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted Share Units were granted on June 15, 2023 and vested on June 15, 2024. F3 · derivative.expiration_date: Restricted Share Units were granted on June 15, 2023 and vested on June 15, 2024. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 15, 2024 Filed Jun 17, 2024 11:20 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 21,108 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-074009 · ownership.xml · nonDerivative · entry 1 LIEBERMAN GERALD M · CIK 0001234346 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,025 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 11:38 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 9,632 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-071068 · ownership.xml · derivative · entry 1 LIEBERMAN GERALD M · CIK 0001234346 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,632 Underlying: Ordinary Shares · 9,632 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on June 6, 2024 and vest on June 6, 2025. F2 · derivative.expiration_date: Restricted share units were granted on June 6, 2024 and vest on June 6, 2025. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 21:12 UTC | Entera Bio Ltd. ENTX · Entity 5464 | GrantStock Option (right to buy) · Derivative | 108,333 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001178913-24-000047 · zk2430732.xml · derivative · entry 1 LIEBERMAN GERALD M · CIK 0001234346 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,333 Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 108,333 shares Expires 2034-01-01 F1 · derivative.exercise_date: The options vest ratably on a quarterly basis over a one-year period that commenced on January 1, 2024. Read SEC document |
| December 22, 2023 Filed Dec 27, 2023 22:00 UTC | Entera Bio Ltd. ENTX · Entity 5464 | PurchaseWarrants (right to buy) · Derivative | 23,952 | $0.13 Strike: $1.00 | $2,994.00 |
DisclosureSEC source: 0001178913-23-003988 · zk2330700.xml · derivative · entry 6 LIEBERMAN GERALD M · CIK 0001234346 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,952 Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 23,952 shares Expires 2028-12-22 F1 · derivative.exercise_price: The Reporting Person entered into a Securities Purchase Agreement with the Issuer on December 20, 2023, pursuant to which, on December 22, 2023, the Reporting Person acquired an aggregate of 23,952 units for a purchase price of $0.835 per unit, each unit consisting of one share of the Issuer's ordinary shares, par value NIS 0.0000769 per share ("Ordinary Shares"), and one warrant, exercisable to purchase an Ordinary Share at an exercise price of $1.00 per share. The purchase price for each unit included $0.125 for the warrant in accordance with Nasdaq rules. F1 · price: The Reporting Person entered into a Securities Purchase Agreement with the Issuer on December 20, 2023, pursuant to which, on December 22, 2023, the Reporting Person acquired an aggregate of 23,952 units for a purchase price of $0.835 per unit, each unit consisting of one share of the Issuer's ordinary shares, par value NIS 0.0000769 per share ("Ordinary Shares"), and one warrant, exercisable to purchase an Ordinary Share at an exercise price of $1.00 per share. The purchase price for each unit included $0.125 for the warrant in accordance with Nasdaq rules. Read SEC document |
| December 22, 2023 Filed Dec 27, 2023 22:00 UTC | Entera Bio Ltd. ENTX · Entity 5464 | PurchaseOrdinary Shares, par value NIS 0.0000769 per share | 23,952 | $0.71 | $17,005.92 |
DisclosureSEC source: 0001178913-23-003988 · zk2330700.xml · nonDerivative · entry 1 LIEBERMAN GERALD M · CIK 0001234346 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 226,961 F1 · price: The Reporting Person entered into a Securities Purchase Agreement with the Issuer on December 20, 2023, pursuant to which, on December 22, 2023, the Reporting Person acquired an aggregate of 23,952 units for a purchase price of $0.835 per unit, each unit consisting of one share of the Issuer's ordinary shares, par value NIS 0.0000769 per share ("Ordinary Shares"), and one warrant, exercisable to purchase an Ordinary Share at an exercise price of $1.00 per share. The purchase price for each unit included $0.125 for the warrant in accordance with Nasdaq rules. F2 · balance_after: The Reporting Person's aggregate amount of Ordinary Shares in the Reporting Person's previous filings was inadvertently overstated by 11,200 shares. The aggregate amount has been properly adjusted in this Form 4. Read SEC document |
| August 21, 2023 Filed Aug 23, 2023 13:28 UTC | Entera Bio Ltd. ENTX · Entity 5464 | PurchaseOrdinary Shares, par value NIS 0.0000769 per share | 20,000 | $0.59 | $11,784.00 |
DisclosureSEC source: 0001178913-23-002974 · zk2330218.xml · nonDerivative · entry 1 LIEBERMAN GERALD M · CIK 0001234346 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 214,209 Read SEC document |
| August 04, 2023 Filed Aug 7, 2023 20:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 15,810 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-044783 · doc4.xml · derivative · entry 2 LIEBERMAN GERALD M · CIK 0001234346 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 15,810 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on August 4, 2022 and vested on August 4, 2023. F3 · derivative.expiration_date: Restricted share units were granted on August 4, 2022 and vested on August 4, 2023. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| August 04, 2023 Filed Aug 7, 2023 20:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 15,810 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-044783 · doc4.xml · nonDerivative · entry 1 LIEBERMAN GERALD M · CIK 0001234346 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,917 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 11:34 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 21,108 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-038220 · doc4.xml · derivative · entry 1 LIEBERMAN GERALD M · CIK 0001234346 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,108 Underlying: Ordinary Shares · 21,108 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on June 15, 2023 and vest on June 15, 2024. F2 · derivative.expiration_date: Restricted share units were granted on June 15, 2023 and vest on June 15, 2024. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| January 02, 2023 Filed Jan 4, 2023 21:20 UTC | Entera Bio Ltd. ENTX · Entity 5464 | GrantStock Option (right to buy) · Derivative | 89,041 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0001178913-23-000053 · zk2328963.xml · derivative · entry 1 LIEBERMAN GERALD M · CIK 0001234346 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,041 Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 89,041 shares Expires 2033-01-02 F1 · derivative.exercise_date: The options vest ratably on a quarterly basis over a one-year period that commenced on January 2, 2023. Read SEC document |
| November 14, 2022 Filed Nov 15, 2022 21:07 UTC | Entera Bio Ltd. ENTX · Entity 5464 | PurchaseOrdinary Shares, par value NIS 0.0000769 per share | 4,000 | $0.59 | $2,360.00 |
DisclosureSEC source: 0001178913-22-004052 · zk2228762.xml · nonDerivative · entry 5 LIEBERMAN GERALD M · CIK 0001234346 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 6,200 F4 · ownership.nature: These shares are owned by a Trust of which the Reporting Person's grandchild is the beneficiary, and the Reporting Person's spouse is the Trustee. The Reporting Person disclaims beneficial ownership of the securities held by this trust, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| November 14, 2022 Filed Nov 15, 2022 21:07 UTC | Entera Bio Ltd. ENTX · Entity 5464 | PurchaseOrdinary Shares, par value NIS 0.0000769 per share | 4,000 | $0.56 | $2,240.00 |
DisclosureSEC source: 0001178913-22-004052 · zk2228762.xml · nonDerivative · entry 4 LIEBERMAN GERALD M · CIK 0001234346 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 6,200 F3 · ownership.nature: These shares are owned by a Trust of which the Reporting Person's grandchild is the beneficiary, and the Reporting Person's spouse is the Trustee. The Reporting Person disclaims beneficial ownership of the securities held by this trust, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| November 14, 2022 Filed Nov 15, 2022 21:07 UTC | Entera Bio Ltd. ENTX · Entity 5464 | PurchaseOrdinary Shares, par value NIS 0.0000769 per share | 4,000 | $0.56 | $2,240.00 |
DisclosureSEC source: 0001178913-22-004052 · zk2228762.xml · nonDerivative · entry 3 LIEBERMAN GERALD M · CIK 0001234346 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 6,200 F2 · ownership.nature: These shares are owned by a Trust of which the Reporting Person's grandchild is the beneficiary, and the Reporting Person's spouse is the Trustee. The Reporting Person disclaims beneficial ownership of the securities held by this trust, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| November 14, 2022 Filed Nov 15, 2022 21:07 UTC | Entera Bio Ltd. ENTX · Entity 5464 | PurchaseOrdinary Shares, par value NIS 0.0000769 per share | 4,000 | $0.56 | $2,240.00 |
DisclosureSEC source: 0001178913-22-004052 · zk2228762.xml · nonDerivative · entry 2 LIEBERMAN GERALD M · CIK 0001234346 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 6,200 F1 · ownership.nature: These shares are owned by a Trust of which the Reporting Person's grandchild is the beneficiary, and the Reporting Person's spouse is the Trustee. The Reporting Person disclaims beneficial ownership of the securities held by this trust, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| November 14, 2022 Filed Nov 15, 2022 21:07 UTC | Entera Bio Ltd. ENTX · Entity 5464 | PurchaseOrdinary Shares, par value NIS 0.0000769 per share | 34,000 | $0.57 | $19,380.00 |
DisclosureSEC source: 0001178913-22-004052 · zk2228762.xml · nonDerivative · entry 1 LIEBERMAN GERALD M · CIK 0001234346 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,209 Read SEC document |
| August 04, 2022 Filed Aug 8, 2022 11:19 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 15,810 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-044693 · doc4.xml · derivative · entry 1 LIEBERMAN GERALD M · CIK 0001234346 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,810 Underlying: Ordinary Shares · 15,810 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on August 4, 2022 and vest on August 4, 2023. F2 · derivative.expiration_date: Restricted share units were granted on August 4, 2022 and vest on August 4, 2023. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| July 21, 2022 Filed Jul 25, 2022 21:16 UTC | Entera Bio Ltd. ENTX · Entity 5464 | PurchaseOrdinary Shares, par value NIS 0.0000769 per share | 19,491 | $1.68 | $32,803.35 |
DisclosureSEC source: 0001178913-22-002762 · zk2228172.xml · nonDerivative · entry 1 LIEBERMAN GERALD M · CIK 0001234346 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,209 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.664 to $1.702, inclusive. The reporting person undertakes to provide to Entera Bio Ltd., an Israeli company ("Entera Bio"), any security holder of Entera Bio, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 11:36 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 14,479 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-037248 · doc4.xml · derivative · entry 2 LIEBERMAN GERALD M · CIK 0001234346 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 14,479 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on June 14, 2021 and vested on June 14, 2022. F3 · derivative.expiration_date: Restricted share units were granted on June 14, 2021 and vested on June 14, 2022. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 11:36 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 14,479 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-037248 · doc4.xml · nonDerivative · entry 1 LIEBERMAN GERALD M · CIK 0001234346 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,107 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| January 18, 2022 Filed Jan 24, 2022 21:15 UTC | Entera Bio Ltd. ENTX · Entity 5464 | PurchaseOrdinary Shares, par value NIS 0.0000769 per share | 700 | $2.81 | $1,965.81 |
DisclosureSEC source: 0001178913-22-000217 · zk2227103.xml · nonDerivative · entry 4 LIEBERMAN GERALD M · CIK 0001234346 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 2,200 F4 · ownership.nature: These shares are owned by a Trust of which the Reporting Person's grandchild is the beneficiary, and the Reporting Person's spouse is the Trustee. The Reporting Person disclaims beneficial ownership of the securities held by this trust, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| January 18, 2022 Filed Jan 24, 2022 21:15 UTC | Entera Bio Ltd. ENTX · Entity 5464 | PurchaseOrdinary Shares, par value NIS 0.0000769 per share | 700 | $2.78 | $1,949.36 |
DisclosureSEC source: 0001178913-22-000217 · zk2227103.xml · nonDerivative · entry 3 LIEBERMAN GERALD M · CIK 0001234346 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 2,200 F3 · ownership.nature: These shares are owned by a Trust of which the Reporting Person's grandchild is the beneficiary, and the Reporting Person's spouse is the Trustee. The Reporting Person disclaims beneficial ownership of the securities held by this trust, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| January 18, 2022 Filed Jan 24, 2022 21:15 UTC | Entera Bio Ltd. ENTX · Entity 5464 | PurchaseOrdinary Shares, par value NIS 0.0000769 per share | 700 | $2.81 | $1,964.27 |
DisclosureSEC source: 0001178913-22-000217 · zk2227103.xml · nonDerivative · entry 2 LIEBERMAN GERALD M · CIK 0001234346 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 2,200 F2 · ownership.nature: These shares are owned by a Trust of which the Reporting Person's grandchild is the beneficiary, and the Reporting Person's spouse is the Trustee. The Reporting Person disclaims beneficial ownership of the securities held by this trust, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| January 18, 2022 Filed Jan 24, 2022 21:15 UTC | Entera Bio Ltd. ENTX · Entity 5464 | PurchaseOrdinary Shares, par value NIS 0.0000769 per share | 700 | $2.80 | $1,960.21 |
DisclosureSEC source: 0001178913-22-000217 · zk2227103.xml · nonDerivative · entry 1 LIEBERMAN GERALD M · CIK 0001234346 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 2,200 F1 · ownership.nature: These shares are owned by a Trust of which the Reporting Person's grandchild is the beneficiary, and the Reporting Person's spouse is the Trustee. The Reporting Person disclaims beneficial ownership of the securities held by this trust, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| January 01, 2022 Filed Jan 11, 2022 21:10 UTC | Entera Bio Ltd. ENTX · Entity 5464 | GrantStock Option (right to buy) · Derivative | 107,557 | $0.00 Strike: $2.82 | $0.00 |
DisclosureSEC source: 0001178913-22-000093 · zk2227046.xml · derivative · entry 2 LIEBERMAN GERALD M · CIK 0001234346 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,557 Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 107,557 shares Expires 2032-01-01 F2 · derivative.exercise_date: The options vest ratably on a quarterly basis over a three-year period that commenced on January 1, 2022. Read SEC document |
| January 01, 2022 Filed Jan 11, 2022 21:10 UTC | Entera Bio Ltd. ENTX · Entity 5464 | GrantStock Option (right to buy) · Derivative | 35,852 | $0.00 Strike: $2.82 | $0.00 |
DisclosureSEC source: 0001178913-22-000093 · zk2227046.xml · derivative · entry 1 LIEBERMAN GERALD M · CIK 0001234346 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,852 Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 35,852 shares Expires 2032-01-01 F1 · derivative.exercise_date: The options vest ratably on a quarterly basis over a one-year period that commenced on January 1, 2022. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 12:19 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 14,479 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-040810 · doc4.xml · derivative · entry 1 LIEBERMAN GERALD M · CIK 0001234346 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,479 Underlying: Ordinary Shares · 14,479 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on June 14, 2021 and vest on June 14, 2022. F2 · derivative.expiration_date: Restricted share units were granted on June 14, 2021 and vest on June 14, 2022. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 09, 2021 Filed Jun 10, 2021 11:42 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 12,668 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-039371 · doc4.xml · derivative · entry 2 LIEBERMAN GERALD M · CIK 0001234346 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 12,668 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on June 9, 2020 and vested on June 9, 2021. F3 · derivative.expiration_date: Restricted share units were granted on June 9, 2020 and vested on June 9, 2021. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 09, 2021 Filed Jun 10, 2021 11:42 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 12,668 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-039371 · doc4.xml · nonDerivative · entry 1 LIEBERMAN GERALD M · CIK 0001234346 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,628 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| June 05, 2021 Filed Jun 8, 2021 11:27 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 6,041 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-038815 · doc4.xml · derivative · entry 2 LIEBERMAN GERALD M · CIK 0001234346 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,041 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on June 5, 2018 and vested on June 5, 2021. F3 · derivative.expiration_date: Restricted share units were granted on June 5, 2018 and vested on June 5, 2021. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 05, 2021 Filed Jun 8, 2021 11:27 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 6,041 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-038815 · doc4.xml · nonDerivative · entry 1 LIEBERMAN GERALD M · CIK 0001234346 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,960 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| August 11, 2020 Filed Aug 13, 2020 20:12 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 7,956 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-046591 · doc4.xml · derivative · entry 2 LIEBERMAN GERALD M · CIK 0001234346 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 7,956 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on August 11, 2017 and vested on August 11, 2020. F3 · derivative.expiration_date: Restricted share units were granted on August 11, 2017 and vested on August 11, 2020. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| August 11, 2020 Filed Aug 13, 2020 20:12 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 7,956 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-046591 · doc4.xml · nonDerivative · entry 1 LIEBERMAN GERALD M · CIK 0001234346 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,919 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 11:34 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 17,621 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-036498 · doc4.xml · derivative · entry 2 LIEBERMAN GERALD M · CIK 0001234346 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 17,621 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on June 11, 2019 and vested on June 11, 2020. F3 · derivative.expiration_date: Restricted share units were granted on June 11, 2019 and vested on June 11, 2020. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 11:34 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 17,621 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-036498 · doc4.xml · nonDerivative · entry 1 LIEBERMAN GERALD M · CIK 0001234346 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,963 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 11:13 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 12,668 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-035784 · doc4.xml · derivative · entry 1 LIEBERMAN GERALD M · CIK 0001234346 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,668 Underlying: Ordinary Shares · 12,668 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on June 9, 2020 and vest on June 9, 2021. F2 · derivative.expiration_date: Restricted share units were granted on June 9, 2020 and vest on June 9, 2021. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.